Search Within

Michael John Mauro

Formats
  1. Meeting Abstract (188)
  2. Journal Article (67)
  3. Review (8)
  4. Correspondence (4)
  5. Research Letter (3)
  6. Book Section (2)
  7. Editorial (2)
  8. Guidelines (2)
Groups
  1. Adult Leukemia (276)
  2. Center for Hematologic Malignancies (276)
  3. Department of Medicine (276)
  4. Hematologic Malignancies, Division of (276)
  5. Biostatistics Service (10)
  6. Epidemiology and Biostatistics (10)

More Groups

People
  1. Raajit Rampal (12)
  2. Ellin Berman (8)
  3. Eytan Stein (8)
  4. Martin Tallman (7)
  5. Amber King (6)
  6. Andriy Derkach (6)

More People

Years
  1. 2025 (7)
  2. 2024 (17)
  3. 2023 (26)
  4. 2022 (33)
  5. 2021 (21)
  6. 2020 (26)

More Years

Publications
  1. Blood (97)
  2. Clinical Lymphoma, Myeloma and Leukemia (44)
  3. Journal of Clinical Oncology (22)
  4. Haematologica (21)
  5. Leukemia (12)
  6. American Journal of Hematology (8)

More Publications

Publishers
  1. American Society of Hematology (101)
  2. Elsevier Inc. (47)
  3. American Society of Clinical Oncology (22)
  4. Ferrata Storti Foundation (21)
  5. Nature Publishing Group (13)
  6. John Wiley & Sons (8)

More Publishers

Results (276)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Tyrosine kinase inhibitor interruptions, discontinuations and switching in patients with chronic-phase chronic myeloid leukemia in routine clinical practice: SIMPLICITY
    Journal Article

    Hehlmann, R.; Cortes, J. E.; Zyczynski, T.; Gambacorti-Passerini, C.; Goldberg, S. L.; Mauro, M. J.; Michallet, M.; Simonsson, B.; Williams, L. A.; Gajavelli, S.; more...
    American Journal of Hematology (2019)

    Fulltext@MSK | Save
  • Bosutinib vs imatinib for newly diagnosed chronic myeloid leukemia in the BFORE trial: 24-month follow-up
    Meeting Abstract

    Cortes, J. E.; Mauro, M. J.; Deininger, M. W. N.; Chuah, C.; Kim, D. W.; Kota, V.; Lipton, J. H.; Rousselot, P. H.; Milojkovic, D.; Le Coutre, P. D.; more...
    Journal of Clinical Oncology (2018)

    Fulltext@MSK | Save
  • Cardiovascular mortality among CML patients in the pre-TKI and TKI eras: A SEER analysis 1992-2004
    Meeting Abstract

    Wang, Q.; Zhang, Y.; Yue, B.; Zhang, Y.; Jiang, C.; Perimbeti, S.; Mauro, M. J.
    Blood (2018)

    Fulltext@MSK | Save
  • Safety and efficacy of combined ruxolitinib and thalidomide in patients with myelofibrosis: Initial results of a phase II study
    Meeting Abstract

    Rampal, R. K.; Verstovsek, S.; Devlin, S. M.; Stein, E. M.; Kadia, T. M.; Mauro, M. J.; Pemmaraju, N.; Alvarez, K.; Ard, N.; Goodman, T.; more...
    Blood (2018)

    Fulltext@MSK | Save
  • Asciminib, a specific allosteric BCR-ABL1 inhibitor, in patients with chronic myeloid leukemia carrying the T315I mutation in a phase 1 trial
    Meeting Abstract

    Rea, D.; Lang, F.; Kim, D. W.; Cortes, J. E.; Hughes, T. P.; Minami, H.; Breccia, M.; Deangelo, D. J.; Hochhaus, A.; Talpaz, M.; more...
    Blood (2018)

    Fulltext@MSK | Save
  • Ruxolitinib in combination with dasatinib and dexamethasone is an active and well-tolerated chemotherapy-sparing oral induction regimen for adults with Philadelphia chromosome-positive ALL: Results of a phase I trial
    Meeting Abstract

    Geyer, M. B.; Burke, P. W.; King, A. C.; Mauro, M. J.; Tallman, M. S.; Levine, R. L.; Sherr, C. J.; Douer, D.; Park, J. H.
    Blood (2018)

    Fulltext@MSK | Save
  • Dosing patterns of dasatinib use in simplicity, an observational study in chronic phase chronic myeloid leukemia (CP-CML) patients (pts) in routine clinical practice
    Meeting Abstract

    Cortes, J. E.; Chen, C.; Mauro, M. J.; Sen, G. P.; Gajavelli, S.; Davis, C.; Goldberg, S. L.
    Blood (2018)

    Fulltext@MSK | Save
  • The significance of leukocytosis in malignancies: A novel paradigm between leukocytosis, G-CSF, myeloid-derived suppressor cells and prognosis
    Meeting Abstract

    Tavakkoli, M.; Wilkins, C.; Mones, J. V.; Mauro, M. J.
    Blood (2018)

    Fulltext@MSK | Save
  • Updated 18-month results from DASFREE: A study evaluating dasatinib discontinuation in patients (pts) with chronic myeloid leukemia in chronic phase (CML-CP) and deep molecular response (DMR)
    Meeting Abstract

    Shah, N. P.; Gutiérrez, J. V. G.; Jiménez-Velasco, A.; Larson, S.; Saussele, S.; Rea, D.; Mahon, F. X.; Levy, M. Y.; Gómez-Casares, M. T.; Pane, F.; more...
    Blood (2018)

    Fulltext@MSK | Save
  • Cardiovascular hospitalization in patients treated with dasatinib or nilotinib in SIMPLICITY, an observational study of chronic-phase chronic myeloid leukemia (CP-CML) patients in routine clinical practice
    Meeting Abstract

    Mauro, M. J.; Chen, C.; Cortes, J. E.; Gambacorti-Passerini, C.; Sen, G. P.; Gajavelli, S.; Davis, C.; Michallet, M.
    Blood (2018)

    Fulltext@MSK | Save